Alzheimer’s disease (AD) is the most common cause of dementia especially in older adults. AD is a progressive neurodegenerative brain disorder that causes a significant disruption of normal brain structure and function. Worldwide, nearly 44 million people have Alzheimer’s. The global cost of Alzheimer’s and dementia is estimated to be $605 billion, which is equivalent to 1% of the entire world’s gross domestic product. It is one of the costliest chronic diseases to society. Amyloid Beta is one of the major proteins that cause the symptoms of this disease. It forms the plaques which block the transfer of signals in neurons and destroy the brain cells. This study focuses on structure based drug designing of memory enhancing drug for Alzheimer’s disease. In order to find the drug we first modeled the protein ’amyloid beta’ using homology modeling. We further proceeded for the docking of the ligands for memory enhancing with the protein ‘amyloid beta’. On the bases on binding affinity and interaction visualization the best ligand was selected and observed for memory enhancing drug. We conclude that Risperidone showed the minimum energy and therefore most stability. Hence, can be used as a very remarkable drug for memory enhancing.